secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001564590-22-028748
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind Q2 2022 revenue $18.9M, net loss narrows to $29.0M; Tyvaso DPI approved
--------------------------------------------------------------------------------

- Commercial product net revenue $12.7M (Afrezza $10.6M, V-Go $2.1M), up 28% YoY; collaboration $5.9M.
- Net loss $29.0M ($0.11/sh) vs $35.5M ($0.14/sh) in Q2 2021; narrowed due to prior-year debt extinguishment loss.
- Tyvaso DPI (pulmonary hypertension) FDA approved May 2022; first manufacturing & royalty revenue from United Therapeutics recognized in Q2.
- V-Go insulin patch acquisition May 31 generated $2.1M net revenue in June; gross profit $0.8M.
- Afrezza gross margin improved to 68% from 56% on higher sales and lower COGS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000156459022028748/0001564590-22-028748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000156459022028748/mnkd-8k_20220809.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-028748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer